PharmaMar (MSE:PHM) has received a notification from the European Commission (EC) informing the Company of its decision...
Multiple Myeloma
Saranno assegnati durante il 124° congresso nazionale della Società Italiana di Medicina Intera (Rimini, 20-23 ottobre 2023)...
On June 27, 2019, the Food and Drug Administration approved daratumumab (DARZALEX, Janssen Biotech, Inc.) in combination...
Luis Mora, Managing Director of the Oncology Business Unit at PharmaMar Which are the strong points...
PharmaMar has announced today a licensing agreement with Boryung Pharm to commercialize the marine-derived anticancer drug Aplidin®...
In the treatment of multiple myeloma, the addition of carfilzomib to a currently accepted two-drug combination...
Multiple Myeloma (MM) is the second most common blood cancer with an incidence of approximately 4-5 new...
There have been significant scientific advances in the field of blood cancers, and leading experts continue to...